ceralasertib
ceralasertib: 15 clinical trials tracked.
ceralasertib evidence translation
What we can confirm
15 tracked trials
What it means
What to watch
Prepared research question
What is verified about ceralasertib, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 4 study sponsors
Related indications
Clinical Trials (15)showing 10 most recent
PRISM: PRecIsion in SCLC Via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab With or Without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Primary endpoint: Screen success rate (Screening)
A Randomized Phase III Trial of Checkpoint Blockade in Lung Cancer Patients in the Adjuvant Setting Based on Pathologic Response Following Neoadjuvant Therapy (CLEAR)
Primary endpoint: Disease free survival (DFS)
A Phase I, Open-label, Fixed-sequence Study to Evaluate the Effect of Ceralasertib on Pharmacokinetics of Drug X, Drug Y and Drug Z in Participants With Advanced Solid Tumours
Primary endpoint: Area under plasma concentration-time curve from time 0 to infinity (AUCinf)
A Phase II, Open-label, Multicentre, Non-comparative, Single-arm Local Study of Ceralasertib Plus Durvalumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy
Primary endpoint: Objective response rate (ORR)
A Phase I, Multi-centre, Open-label, Dose Exploration Study to Assess the Safety and Tolerability of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours
Primary endpoint: The number of subjects with dose-limiting toxicity, as defined in the protocol.
A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy: LATIFY
Primary endpoint: Overall Survival (OS)
A Phase II Study of Chemo-Immunotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Big Ten Cancer Research Consortium BTCRC-LUN18-363
Primary endpoint: Progression Free Survival (PFS)
Phase II Trial of Olaparib in Combination With Ceralasertib in Patients With Recurrent Osteosarcoma
Primary endpoint: Cohort 1 Event Free at 4 months
ATARI: ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss
Primary endpoint: Confirmed overall objective response rate (complete or partial response) as defined by RECIST version 1.1.
PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer
Primary endpoint: Cohorts B and C co-primary endpoint #1: Change in mean proliferation index (as measured by tumour cell Ki67 staining) post WOP intervention within post-treatment biopsy compared to pre-treatment baseline biopsy.